Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
135.17M | 138.39M | 157.75M | 205.75M | 12.36M | 9.54M | Gross Profit |
136.31M | 134.84M | 154.79M | 62.70M | -159.50M | -46.41M | EBIT |
-63.64M | -95.67M | -78.20M | 12.18M | -202.85M | -71.52M | EBITDA |
-60.17M | -77.40M | -24.17M | 13.70M | -201.66M | -70.64M | Net Income Common Stockholders |
-68.20M | -80.94M | -29.73M | 9.35M | -206.86M | -71.36M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
216.95M | 237.03M | 292.00M | 391.88M | 370.49M | 462.89M | Total Assets |
331.79M | 344.07M | 429.40M | 450.39M | 392.81M | 476.46M | Total Debt |
38.99M | 28.55M | 30.22M | 90.87M | 67.61M | 17.87M | Net Debt |
-177.96M | -208.48M | -261.79M | -301.01M | -302.88M | -445.02M | Total Liabilities |
98.03M | 103.09M | 150.89M | 180.07M | 164.60M | 79.90M | Stockholders Equity |
233.76M | 240.98M | 278.51M | 270.31M | 228.21M | 396.55M |
Cash Flow | Free Cash Flow | ||||
-89.09M | -60.40M | -21.00M | 24.27M | -138.45M | -44.60M | Operating Cash Flow |
-89.55M | -59.75M | -18.10M | 31.99M | -135.04M | -42.86M | Investing Cash Flow |
-545.00K | -648.00K | -2.90M | -7.73M | -3.41M | -1.74M | Financing Cash Flow |
18.39M | 5.42M | -24.09M | -2.86M | 48.02M | 436.14M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $337.38M | ― | -27.40% | ― | 15.40% | 35.42% | |
55 Neutral | $447.68M | ― | -62.43% | ― | -0.90% | -89.51% | |
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
44 Neutral | $328.05M | ― | -2159.50% | ― | ― | 14.39% | |
43 Neutral | $411.09M | ― | -56.24% | ― | ― | 9.22% | |
41 Neutral | $471.75M | ― | -39.06% | ― | ― | -48.01% |
On June 6, 2025, Arcturus Therapeutics held its annual stockholders meeting where key proposals were voted on, including the election of nine directors to the Board, approval of executive compensation, and the ratification of Deloitte as the independent accounting firm for 2025. All proposals were approved, indicating strong shareholder support for the company’s leadership and strategic direction.
The most recent analyst rating on (ARCT) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.